Cargando…

Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study

SIMPLE SUMMARY: Patients with B-cell malignancies benefit from the third vaccination against SARS-CoV-2 with regards to antibody production. In this cohort, patients with B-cell malignancies experienced greater difficulties in developing neutralizing antibodies, particularly under active treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wirth, Stella Rosa Maria, Podar, Klaus, Pecherstorfer, Martin, Wohlfarth, Philipp, Jaeger, Ulrich, Singer, Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856293/ https://www.ncbi.nlm.nih.gov/pubmed/36672473 http://dx.doi.org/10.3390/cancers15020524

Ejemplares similares

Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study
por: Pirich, Theo, et al.
Publicado: (2018)

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients
por: Singer, Josef, et al.
Publicado: (2021)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
por: Vallet, Sonia, et al.
Publicado: (2018)

Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma—A Single-Center Retrospective Cohort Study
por: Huber, Fabian, et al.
Publicado: (2021)

Effect of cachexia on bone turnover in cancer patients: a case-control study
por: Zwickl, Hannes, et al.
Publicado: (2021)

Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015
por: Hintermair, Sarah, et al.
Publicado: (2018)

Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic Krems
por: Singer, Josef, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
por: Wagner, Gernot, et al.
Publicado: (2020)

Targeting the Tumor Microenvironment: Focus on Angiogenesis
por: Fan, Fengjuan, et al.
Publicado: (2012)

REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection
por: Bronstein, Yotam, et al.
Publicado: (2022)

Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
por: Tsipotis, Evangelos, et al.
Publicado: (2023)

New Insights Into SARS-CoV-2-specific Antibody Levels in Kidney Transplantation Recipients After Three Vaccination Doses
por: Kang, Hyunhye, et al.
Publicado: (2024)

Screening for SARS-CoV-2 antibodies to save vaccine doses
por: Fenollar, Florence, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies
por: Weber, Myriam C., et al.
Publicado: (2021)

Side-By-Side Evaluation of Three Commercial ELISAs for the Quantification of SARS-CoV-2 IgG Antibodies
por: Girl, Philipp, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients
por: Tillmann, F. P., et al.
Publicado: (2021)

Diagnostic Properties of Three SARS-CoV-2 Antibody Tests
por: Basgalupp, Suelen, et al.
Publicado: (2021)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
por: Markewitz, Robert, et al.
Publicado: (2022)

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
por: Singanallur, Nagendrakumar B., et al.
Publicado: (2022)

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
por: Lim, Sean H., et al.
Publicado: (2022)

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
por: Ariën, Kevin K., et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody response after three doses of mRNA1273 vaccine and COVID-19 in hemodialysis patients
por: Wang, Xiaoling, et al.
Publicado: (2022)

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
por: Debes, Amanda K., et al.
Publicado: (2022)

Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
por: Chapuy-Regaud, Sabine, et al.
Publicado: (2021)

Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology
por: Perkmann, Thomas, et al.
Publicado: (2023)

Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible
por: Finsterer, Josef
Publicado: (2022)

Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection
por: Knaus, Hanna A., et al.
Publicado: (2021)

Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
por: Iversen, Patrick L, et al.
Publicado: (2021)

Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections
por: Macrae, Kathryn, et al.
Publicado: (2022)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
por: Hsieh, Szu-Min, et al.
Publicado: (2022)

Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
por: Saresella, Marina, et al.
Publicado: (2022)

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
por: Gressens, Simon B., et al.
Publicado: (2022)

Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients.
por: Zojer, N., et al.
Publicado: (1997)

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
por: Cho, Alice, et al.
Publicado: (2022)

Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
por: Yang, Zhi-Rong, et al.
Publicado: (2023)

Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies
por: Bubonja-Šonje, Marina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r217c5e5k9u6oripi6rabokaj8